FOCUS – THE UK’S BIO-ENGINEERING INDUSTRY
FROM THE INDUSTRY – BIOTECH
EZ-Spread Plating Beads are just one of Amsbio’s products Alex Sim CEO of Amsbio
Does the industry agree with the Committee’s fi ndings? In this Q&A, Eurolab caught up with Alex Sim CEO of UK-based biotechnology company Amsbio for his insights
PLEASE GIVE ME A BRIEF OVERVIEW OF YOUR COMPANY AND ITS AREA OF EXPERTISE AMS Biotechnology (Amsbio) is headquartered in Abingdon in the UK but is now owned by the Europa Biosite group of companies. The company leads in the supply of high-quality reagents and tools for life-sciences research specialising in innovative cell- culture solutions, immunological reagents, and emerging technologies that support areas such as cell therapy and precision medicine.
DO YOU AGREE THAT THE UK IS FALLING BEHIND IN TERMS OF SCIENTIFIC INNOVATION AND HOW HOW DO YOU PREVENT FOREIGN COMPETITORS LEAPFROGGING YOUR TECHNOLOGY OR EXPLOITING YOUR BREAKTHROUGHS? We agree that that the UK is currently falling behind in scientifi c innovation; a trend partially driven by factors such as Brexit and the migration of top scientists back to Europe as a result.
However, life sciences is a global endeavour. The focus
should not be solely on protecting British breakthroughs from being ‘leapfrogged’ by foreign competitors; instead, it should be on investing in our own internal innovation and collaboration internationally. The real measure of success lies not in national borders but in engaging with the best global practices.
THE REPORT SAID THAT THE UK SHOULD IMPROVE SKILLS AND REGULATION AND DEVELOP A STRATEGY - DO YOU AGREE, AND WHAT WOULD YOU LIKE TO SEE IN A NATIONAL SCIENTIFIC STRATEGY? A cohesive national scientifi c strategy would provide clear, top-down support that directly aligns research priorities with industry needs. Such a strategy could bridge the gap between academic discovery and commercial application by streamlining funding and providing a hub for innovation. For example, in the UK, a promising reagent might be
informally shared among colleagues, in the US, similar innovations often lead directly to the formation of start-up companies. This demonstrates the benefi ts of a well-co-
www.scientistlive.com 9
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
